Press Release: Novartis announces FDA filing -2-
particular, our expectations regarding such products could be affected
by, among other things, the uncertainties inherent in research and
development, including clinical trial results and additional analysis of
existing clinical data; regulatory actions or delays or government
regulation generally; global trends toward health care cost containment,
including government, payor and general public pricing and reimbursement
pressures; our ability to obtain or maintain proprietary intellectual
property protection; the particular prescribing preferences of
physicians and patients; general political and economic conditions;
safety, quality or manufacturing issues; potential or actual data
security and data privacy breaches, or disruptions of our information
technology systems, and other risks and factors referred to in Novartis
AG's current Form 20-F on file with the US Securities and Exchange
Commission. Novartis is providing the information in this press release
as of this date and does not undertake any obligation to update any
forward-looking statements contained in this press release as a result
of new information, future events or otherwise.
Novartis is reimagining medicine to improve and extend people's lives.
As a leading global medicines company, we use innovative science and
digital technologies to create transformative treatments in areas of
great medical need. In our quest to find new medicines, we consistently
rank among the world's top companies investing in research and
development. Novartis products reach more than 750 million people
globally and we are finding innovative ways to expand access to our
latest treatments. About 105 000 people of more than 140 nationalities
work at Novartis around the world. Find out more at www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at
For Novartis multimedia content, please visit
For questions about the site or required registration, please contact
 American Academy of Ophthalmology. Age-related macular degeneration
preferred practice patterns. Available at:
Accessed March 2019.  van Lookeren Campagne M, et al. Mechanisms of
age-related macular degeneration and therapeutic opportunities. J
Pathol. 2014; 232(2):151-64. doi: 10.1002/path.4266. 
ClinicalTrials.gov. Identifier NCT02307682. Available at
https://clinicaltrials.gov/ct2/show/NCT02307682 (link is external).
Accessed January 2019.  ClinicalTrials.gov. Identifier NCT02434328.
Available at https://clinicaltrials.gov/ct2/show/NCT02434328 (link is
external). Accessed January 2019.  Dugel P, et al. HAWK & HARRIER:
48-week results of 2 multi-centered, randomized, double-masked trials of
brolucizumab versus aflibercept for neovascular AMD. Presented at: The
American Academy of Ophthalmology 2017 Annual Meeting on November 10,
2017, New Orleans.  Dugel P, et al. Phase 3, randomized,
double-masked, multi-center trials of brolucizumab versus aflibercept
for neovascular AMD: 96-week results from the HAWK and HARRIER studies.
Presented at: The American Academy of Ophthalmology on October 27, 2018,
Chicago.  Escher D, et al. Single-chain antibody fragments in
ophthalmology. Oral presentation at EURETINA congress. 2015. Abstract.
 Nimz EL, et al. Intraocular and systemic pharmacokinetics of
brolucizumab (RTH258) in nonhuman primates. The Association for Research
in Vision and Ophthalmology (ARVO) annual meeting. 2016. Abstract 4996.
 Gaudreault J, et al. Preclinical pharmacology and safety of
ESBA1008, a single-chain antibody fragment, investigated as potential
treatment for age related macular degeneration. ARVO Annual Meeting
abstract. Invest Ophthalmol Vis Sci 2012;53:3025.
http://iovs.arvojournals.org/article.aspx?articleid=2354604 (link is
external). Accessed January 2019.  Tietz J, et al. Affinity and
Potency of RTH258 (ESBA1008), a Novel Inhibitor of Vascular Endothelial
Growth Factor A for the Treatment of Retinal Disorders. IOVS. 2015;
56(7):1501.  Qazi Y, et al. Mediators of ocular angiogenesis. J.
Genet. 2009;88(4):495-515.  Kim R. Introduction, mechanism of action
and rationale for anti-vascular endothelial growth factor drugs in
age-related macular degeneration. Indian J Ophthalmol.
2007;55(6):413-415.  Wong, W.L. et al. Global prevalence of
age-related macular degeneration and disease burden projection for 2020
and 2040: a systematic review and met analysis.
Lancet Glob Health
. 2014 Feb;2 (2):e106-16.  World Health Organization. Priority eye
diseases: Age-related macular degeneration. Available at
http://www.who.int/blindness/causes/priority/en/index7.html (link is
external). Accessed January 2019.  NHS Choices. Macular
Degeneration. Available at
(link is external). Accessed January 2019.  NHS Choices. Macular
Degeneration - Symptoms. Available at
(link is external). Accessed January 2019.
# # #
Novartis Media Relations
Central media line: +41 61 324 2200
Eric Althoff Martin DeBenedetto
Novartis Global Media Relations Director, Communications
+41 61 324 7999 (direct) +1 862 778-7619 (direct)
+41 79 593 4202 (mobile) +1 973 738-4104 (mobile)
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
Central North America
Samir Shah +41 61 324 7944 Richard Pulik +1 862 778 3275
Pierre-Michel Bringer +41 61 324 1065 Cory Twining +1 862 778 3258
Thomas Hungerbuehler +41 61 324 8425
Isabella Zinck +41 61 324 7188
Media release (PDF): http://hugin.info/134323/R/2241647/884276.pdf
This announcement is distributed by West Corporation on behalf of West
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the information
Source: Novartis International AG via Globenewswire
--- End of Message ---
Novartis International AG
P.O. Box Basel Switzerland
WKN: 904278;ISIN: CH0012005267;
(END) Dow Jones Newswires
April 15, 2019 16:05 ET (20:05 GMT)